Chlamydia Infection Diagnostics and Therapeutics Market
Chlamydia Infection Diagnostics and Therapeutics Market (Product Type - Diagnostics (Nucleic Acid Amplification Tests (NAATs) and Direct Fluorescent Tests) and Therapeutics (Macrolides, Quinolones, Sulfonamides, Tetracycline, and Aminopenicillins); End Users - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Category : Pharmaceutical
- Format :
Press Release :
Global Chlamydia Infection Diagnostics and Therapeutics Market: Snapshot
The chlamydia infection diagnostics and therapeutics market unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities, especially in developing economies across regions such as Asia Pacific and Latin America. The market expected to exhibit healthy growth in the near future due to the increasing focus on treatment of sexually transmitted diseases globally. There is a need for enhanced techniques of diagnosis of pelvic inflammatory disease and for signs of chlamydial infection that expects women at high threat of tubal damage. Chlamydia trachomatis is the most commonly reported sexually transmitted infection in the world. The rate of reported chlamydia infection diagnoses continues to increase.
Transparency Market Research estimates that the global Chlamydia Infection diagnostics and therapeutics market will expand at a robust CAGR of 6.0% over the forecast period between 2017 and 2025.
Nucleic Acid Amplification Tests to Remain Most Preferred
In terms of product type, the global chlamydia infection diagnostics market has been segmented in the report into nucleic acid amplification tests (NAATs), and direct fluorescent tests. Of these, the segment of nucleic acid amplification is expected to steadily expand, albeit at a moderate CAGR, over the report’s forecast period. The segment will be closely followed by the direct fluorescent in 2016 and through the forecast period. The continuous rise in the number of diagnosed cases of chlamydia is due to the preference shift towards more the extensive diagnostic tests and testing of asymptomatic people with greater sensitivity that is shift from culture based methods to nucleic acid amplification tests (NAATs)
Chlamydia infection therapeutics market is segmented by product type into macrolides, quinolones, sulfonamides, tetracycline, Aminopenicillins. Physician prescription preference for antibiotics such as macrolides and tetracycline is driving the growth of chlamydia infection therapeutics market. The segment of macrolides is expected to expand at a promising pace during the report’s forecast period. This is followed by the direct fluorescent sub-segment, which contributed for second highest share in the global Chlamydia Infection diagnostics market in 2016.
North America and Europe Markets Continue to Exhibit Strong Growth
In terms of revenue, North America was the largest regional market for chlamydia infection diagnostics and therapeutics market, and accounted for a share of over 55.5% of the chlamydia infection diagnostics market and over 44.5% of the chlamydia infection therapeutics market in 2016. Supremacy of North America has been attributed to well establish health care industry, increasing incidence of chlamydia infection among population, and availability of well-defined reimbursement policies from public and private health insurance firms. Better diagnostic and treatment rates, in part due to proactive awareness initiatives undertaken by public and private bodies, have also led to North America gaining the predominant share in the global market.
The Asia Pacific market, owing to its vast potential to quickly adopt to new therapies owing to the presence of several strengthening economies, held the third position in the global market in terms of revenue contribution in 2016. The regional market continues to be price-sensitive and features the availability of cheaper generics as compared to North America and Europe. Key elements such as large pool of potential patients, implementation of government initiatives aimed at improving health care access, increasing incidence of chlamydia infection, improving infrastructure, and growing health care expenditure would drive the growth of the market in Asia Pacific.
Some of the leading companies operating in the global chlamydia infection diagnostics and therapeutics market are Bio Rad laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher, bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.
Global Chlamydia Infection Diagnostics and Therapeutics Market: Overview
Chlamydial infection, caused by Chlamydia trachomatis, is the most common contagious sexually transmitted infection and results in significant economic cost and morbidity worldwide. Occurs most commonly in young sexually active population, C. trachomatis causes urethritis in men and cervicitis in women, as well as extra-genital infections, including pharyngeal and rectal infections. Asymptomatic infections are common in both men and women. Untreated chlamydial infection may cause severe abnormalities related with the upper reproductive tract, mainly in younger women, including salpingitis, infertility, and ectopic pregnancy. Maternal infection is associated with serious adverse results in neonates, such as low birth weight, preterm birth, nasopharyngeal infection, chlamydial conjunctivitis, and pneumonia. C. trachomatis can be diagnosed by culture, Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, and others (ELISAs).
Global Chlamydia Infection Diagnostics and Therapeutics Market: Scope
This report on the global chlamydia infection diagnostics and therapeutics market analyzes the current and future prospects of the market. The markets of diagnostics and therapeutics are independently analyzed as two separate markets within the report. The market for chlamydia infection therapeutics is segmented based on product type, end-user and region, while the market for chlamydia infection diagnostics is segmented on the basis of diagnostics and end-user. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market related factors such as global incidence/prevalence of sexual transmitted infection, global incidence/prevalence of eye infection, cost of sexual transmitted infection in U.S (2010-2015), and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global chlamydia infection diagnostics and therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.
Global Chlamydia Infection Diagnostics and Therapeutics Market: Segmentation
Based on product type, the global chlamydia infection diagnostics and therapeutics market has been segmented into diagnostics and therapeutics. Chlamydia infection diagnostics segment further segmented into nucleic acid amplification tests (NAATs), direct fluorescent tests, and others (ELISAs).
The therapeutics used for treatment of chlamydia infection include Macrolides, Quinolones, Sulfonamides, Tetracycline, and Aminopenicillins. Macrolides are the antibiotics most commonly prescribed to treat chlamydia infection.
Geographically, the global chlamydia infection diagnostics and therapeutics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries for the chlamydia infection therapeutics market. These include the U.S., Canada, Germany, France, Spain, Italy, U.K., Russia, China, Japan, India, Brazil, Mexico, GCC countries, and South Africa. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global chlamydia infection diagnostics and therapeutics market. The report also profiles major players in the chlamydia infection diagnostics and therapeutics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Bio Rad laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher, bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company
The global chlamydia infection therapeutics and diagnostics market has been segmented as follows:
|
by Product
|
|
|
by End-user |
|
|
by Geography |
|
